Roche halts SERD from Seragon, reports earnings

Roche (SIX:ROG; OTCQX:RHHBY) disclosed in its Thursday earnings report that it will discontinue development of RG6047 (GDC-0927). The selective estrogen receptor

Read the full 212 word article

User Sign In